Article
The prevalence of the activating JAK2 tyrosine kinase mutation in chronic porto-splenomesenteric venous thrombosis.
Alimentary pharmacology & therapeutics - 1 Jun 2010
Orr D W, Patel R K, Lea N C, Westbrook R H, O'Grady J G, Heaton N D, Pagliuca A, Mufti G J, Heneghan M A
Abstract excerpt
BACKGROUND: Occult myeloproliferative disorders (MPD) are present in 25% of patients with chronic portal, splenic and mesenteric venous thrombosis (PSMVT). A somatic mutation of JAK2 (JAK2V617F) can be used to identify patients with latent MPD. AIM: We evaluated the prevalence and clinical significance of JAK2V617F in patients with chronic PSMVT. METHODS: Allele-specific polymerase chain reaction was performed to...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.